Multidisciplinary approach to psoriasis in the Spanish National Health System: A social return on investment study

  • Gregorio Carretero Dermatology and Venereology Spanish Academy, Madrid - Spain
  • David Moreno Department of Dermatology, Virgen Macarena Hospital, Seville - Spain
  • Almudena González Domínguez Max Weber Institute, Madrid - Spain
  • David Trigos Acción Psoriasis, Psoriasis Patients and Relatives Association, Barcelona - Spain
  • Albert Ledesma Generalitat de Catalunya, Barcelona - Spain
  • Esther Sarquella Generalitat de Catalunya, Barcelona - Spain
  • María Merino Max Weber Institute, Madrid - Spain
  • Carles Blanch Novartis Pharmaceuticals, Madrid - Spain
  • SROI Psoriasis Group
Keywords: health economics, health care utilization, SROI, social impact, psoriasis, resource optimization

Abstract

Introduction: Psoriasis is a chronic disease in which patients feel stigmatization, social rejection, and suffer from low self-esteem. There are still unmet needs that make it necessary to define a new multidisciplinary approach to provide benefits not only to patients and their families but also to the Spanish National Health System (SNHS) and society. The aim was to define a new approach to better address the unmet needs of patients with psoriasis within the SNHS and to measure its impact from a social perspective, that is, in clinical, health care, economic, and social terms.

Methods: Multidisciplinary experts identified, agreed on, and selected several health care interventions that were feasible for implementation in the SNHS. This process was carried out in four different areas: diagnosis, mild psoriasis, moderate psoriasis, and severe psoriasis. To estimate investment and social return, the social return on investment (SROI) method was used.

Results: The new approach to psoriasis management in the SNHS comprised 18 proposals. The investment needed for the implementation of this new approach would amount to €222.77 million and its return to €1,123.11 million. This would yield a SROI ratio of €5.04 for every euro invested. 

Conclusion: The new approach to psoriasis management would yield a positive social return. The results will allow optimal strategic planning adapted to each assistance situation, to achieve a comprehensive and multidisciplinary approach.

References

Strober BE, van der Walt JM, Armstrong AW, et al. Clinical goals and barriers to effective psoriasis care. Dermatol Ther (Heidelb). 2019 Mar;9(1):5-18.

Grozdev I, Korman N, Tsankov N. Psoriasis as a systemic disease. Clin Dermatol. 2014 May-Jun;32(3):343-350.

World Health Organization. Strategic resource allocation. Report of the Programme, Budget and Administration Committee of the Executive Board to the Sixty-seventh World Health Assembly [Internet]. 2014 [cited 2017 Feb 17]. http://apps.who.int/iris/bitstream/handle/10665/152547/A67_9-en.pdf?sequence=1&isAllowed=y Accessed February 17, 2017.

Chren M-M, Weinstock MA. Conceptual issues in measuring the burden of skin diseases. J Investig Dermatol Symp Proc. 2004 Mar;9(2):97-100.

Obradors M, Figueras M, Paz S, Comellas M, Lizán L. Costs of psoriasis in Europe. A systematic review of the literature. Value Health. 2014 Nov 1;17(7):A606.

Gupta R, Debbaneh MG, Liao W. Genetic epidemiology of psoriasis. Curr Dermatol Rep. 2014 Mar;3(1):61-78.

Ferrándiz C, Carrascosa JM, Toro M. Prevalencia de la psoriasis en España en la era de los agentes biológicos. Actas Dermosifiliogr. 2014;105(5):504-509.

Carrascosa J, Pujol R, Daudén E, et al. A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: Phase II). J Eur Acad Dermatol Venereol. 2006 Aug;20(7):840-845.

Puig L, Bordas X, Carrascosa JM, et al. Documento de consenso sobre la evaluación y el tratamiento de la psoriasis moderada/grave del Grupo Español de Psoriasis de la Academia Española de Dermatología y Venereología. Actas Dermosifiliogr. 2009;100(4):277-286.

Rapp SR, Feldman SR, Exum ML, Fleischer AB, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999 Sep;41(3 Pt 1):401-407.

Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol. 2006 Oct;155(4):729-736.

Moreno-Ramírez, Fonseca E, Herranz P, Ara M. Realidad terapéutica de la psoriasis moderada-grave en España. Encuesta de opinión. Actas Dermosifiliogr. 2010;101(10):858-865.

Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M. Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol. 2010 Sep;24(9):989-1004.

Richards HL, Chong SLP, Mason DL, Griffiths CE. The impact of psoriasis on healthy partners of patients with psoriasis. Br J Dermatol. 2002;147(Suppl 62):40.

Ros S, Puig L, Carrascosa JM. Discapacidad acumulada en el transcurso vital: la cicatriz de la psoriasis en la vida del paciente. Actas Dermosifiliogr. 2014;105(2):128-134.

Sampogna F, Tabolli S, Söderfeldt B, et al. Measuring quality of life of patients with different clinical types of psoriasis using the SF-36. Br J Dermatol. 2006 May;154(5):844-849.

Kurd SK, Troxel AB, Crits-Christoph P, Gelfand JM. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010 Aug;146(8):891-895.

Nicholls J, Lawlor E, Neitzert E, Goodspeed T. A guide to Social Return on Investment [Internet]. UK: The SROI Network. Accounting for Value; 2012. http://www.socialvalueuk.org/app/uploads/2016/03/The%20Guide%20to%20Social%20Return%20on%20Investment%202015.pdf Accessed February 1, 2017.

Instituto Nacional de Estadística. Estadística del Padrón Continuo a 1 de enero de 2015. [Internet]. 2015 [cited 2016 Mar 1]. http://www.ine.es Accessed March 1, 2016.

Instituto Nacional de Estadística. Media anual del índice general de Precios de Consumo. Base 2011 [Internet]. 2016. http://www.ine.es/jaxiT3/Tabla.htm?t=10305&L=0 Accessed February 26, 2017.

CCEMG—EPPI-Centre Cost Converter v.1.4 [Internet]. [cited 2016 Mar 28]. http://eppi.ioe.ac.uk/costconversion/ Accessed February 26, 2017.

Huerta C, Rivero E, Rodríguez LAG. Incidence and risk factors for psoriasis in the general population. Arch Dermatol. 2007 Dec;143(12):1559-1565.

Burgos-Pol R, Martínez-Sesmero JM, Ventura-Cerdá JM, Elías I, Caloto MT, Casado MÁ. The cost of psoriasis and psoriatic arthritis in 5 European countries: a systematic review. Actas Dermosifiliogr. 2016 Sep;107(7):577-590.

Obradors M, Paz S, Comellas M, Lizán L. Carga económica de la psoriasis en Europa. Revisión de la literatura [Internet]. XXXIV edición de las Jornadas de Economía de la Salud; 2015. https://www.outcomes10.com/wp-content/uploads/2015/02/28.pdf Accessed February 25, 2016.

Polistena B, Calzavara-Pinton P, Altomare G, et al. The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice. J Eur Acad Dermatol Venereol. 2015 Dec;29(12):2411-2416.

Maza A, Richard MA, Aubin F, et al. Significant delay in the introduction of systemic treatment of moderate to severe psoriasis: a prospective multicentre observational study in outpatients from hospital dermatology departments in France. Br J Dermatol. 2012 Sep;167(3):643-648.

Luelmo J, Gratacós J, Martínez-Losa MM, et al. Experiencia de 4 años de funcionamiento de una unidad multidisciplinar de psoriasis y artritis psoriásica. Reumatol Clin. 2014;10(3):141-146.

Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014 May;70(5):871-881. e1-e30.

Batalla A, Suh-Oh HJ, Salgado-Boquete L, Abalde T, de la Torre C. Teledermatología. Capacidad para reducir consultas presenciales según el grupo de enfermedad. Piel (Barc). 2016;31(3):156-163.

Vaño-Galván S, Hidalgo A, Aguayo-Leiva I, et al. Teledermatología diferida: análisis de validez en una serie de 2.000 observaciones. Actas Dermosifiliogr. 2011;102(4):277-283.

Lafuente-Urrez RF, Martin de Aguilera Moro MC. La enfermería: ¿una colaboración necesaria para el control de nuestros pacientes afectos de psoriasis? Actas Dermosifiliogr. 2014;105(3):213-215.

Ruiz Moral R, Peralta Munguia L, Pérula de Torres LÁ, et al. Opiniones y percepciones de los pacientes sobre su participación en la toma de decisiones en las consultas de medicina de familia. Aten Primaria. 2012;44(1):5-12.

Ayala F, Sampogna F, Romano GV, et al. The impact of psoriasis on work-related problems: a multicenter cross-sectional survey. J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1623-1632.

Published
2020-07-17
How to Cite
CarreteroG., MorenoD., González DomínguezA., TrigosD., LedesmaA., SarquellaE., MerinoM., BlanchC., & Psoriasis GroupS. (2020). Multidisciplinary approach to psoriasis in the Spanish National Health System: A social return on investment study. Global & Regional Health Technology Assessment, 7(1), 50-56. https://doi.org/10.33393/grhta.2020.2146
Section
Original Research Article